CR
CRSP.O
—
NASDAQ
Biotechnology & Life-Science Tools
Crsp.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-18 933,6 %
ROE
-30,3 %
Net margin
-16 569,8 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
10,7k
Day range
$51,11–$54,52
Prev close
$51,59
Open
$51,71
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
CRSP.O is a healthcare diagnostics company that provides clinical laboratory services and data analytics solutions to healthcare providers, payers, and life sciences organizations.
Business. CRSP.O is a healthcare diagnostics company that provides clinical laboratory services and data analytics solutions to healthcare providers, payers, and life sciences organizations.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
BUY24 analysts
13 buy11 hold0 sell
Avg 12m price target82,53
Analyst recommendations
24 analysts · consensus BuyBuy13
Hold11
Sell0
12-month price target
82,53
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
24 analysts · indicative
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-30,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CRSP.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
CRSP.O is a healthcare diagnostics company that provides clinical laboratory services and data analytics solutions to healthcare providers, payers, and life sciences organizations.
Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
AI synthesis
GENERATEDCRSP.O has a highly liquid capital structure, with a current ratio of 13.32, indicating strong short-term liquidity. The company is entirely equity-funded, with no long-term debt, and a debt-to-equity ratio of 0.0. However, the company is experiencing negative cash flows, with operating cash flow of -$345.01 million and free cash flow of -$588.03 million. This suggests that the company is not generating sufficient cash from operations to sustain its activities and is likely relying on equity financing or asset sales to fund operations.
Profitability metrics are deeply negative, with a return on equity of -30.26% and a return on assets of -25.67%. These figures are significantly below the industry median for biotechnology and medical research firms, which typically exhibit positive returns during growth phases. The company reported a net loss of $581.60 million and an operating loss of $664.57 million, indicating that it is not yet achieving operational profitability.
The company's revenue is concentrated in a single business line, as disclosed in its financial segments, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks, such as regulatory changes or shifts in healthcare reimbursement models. No specific geographic breakdown is available in the current dataset, but the absence of international revenue reporting suggests a U.S.-centric business model.
Growth trajectory is currently negative, with the company reporting a revenue of $3.51 billion but experiencing a net loss of $581.60 million. Analysts have provided a wide range of price targets, from $33.00 to $291.00, with a mean of $81.25 and a median of $78.00. The mean recommendation score of 2.21 suggests a generally positive outlook, but the wide dispersion in price targets indicates uncertainty about the company's future performance. No specific revenue growth rates or outlooks for the current or next fiscal year are provided in the available data.
Risk factors include the company's negative cash flows and net losses, which could lead to increased reliance on equity financing. The risk assessment indicates low dilution risk, but the company's negative free cash flow and operating cash flow suggest potential liquidity challenges if equity financing is not sustained. No immediate filing-based liquidity or dilution flags were detected, but the company's financial position remains precarious without a path to positive cash flow.
Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. No specific recent filings or transcripts are available in the current dataset, but the company's financial performance suggests ongoing operational challenges that may require strategic adjustments or additional capital.
Key takeaways
- CRSP.O is a highly liquid but unprofitable healthcare diagnostics company with a current ratio of 13.32 and no long-term debt.
- The company is experiencing significant net losses and negative cash flows, with a return on equity of -30.26% and a return on assets of -25.67%.
- Revenue is concentrated in a single business line, with no geographic diversification disclosed in the available data.
- Analysts have provided a wide range of price targets, from $33.00 to $291.00, with a mean of $81.25 and a median of $78.00.
- The company faces liquidity risks due to negative operating and free cash flows, but no immediate dilution or liquidity flags were detected in the latest filings.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$49,92
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$1.92B
Net cashⓘ
—
Current ratioⓘ
13.3
Debt / equityⓘ
0.0
ROAⓘ
-25.7%
ROEⓘ
-30.3%
Cash conversionⓘ
59.0%
CapEx / revenueⓘ
-7.4%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships6 disclosed relationships · 2 types · extracted from filings & disclosures
Partners2
ELI LILLY AND COMPANYLLY.NPartner100%Source ↗
VERTEX PHARMACEUTICALS INCORPORATEDVRTX.OPartner100%Source ↗
Subsidiaries4
EX21:003bb592cf42EX21:003bb592cf42Subsidiarie97%
EX21:1d4b5f6dd0eaEX21:1d4b5f6dd0eaSubsidiarie97%
EX21:a7f067d6a343EX21:a7f067d6a343Subsidiarie97%
EX21:b7bcf4250504EX21:b7bcf4250504Subsidiarie97%
Supply chain
Vendors → CRSP ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs CRSP · multiples and returns
IQ
IQV—
Iqvia Holdings Inc
$181,94
30,9B USDP/E
22,7x
— vs self
Div yield
—
— vs self
ROE
21,9 %
+53,9 vs self
CR
CRL—
Charles River Laboratories
$230,87
11,4B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-4,6 %
+27,5 vs self
ME
MEDP—
Medpace Holdings Inc
$576,00
16,7B USDP/E
34,4x
— vs self
Div yield
—
— vs self
ROE
75,4 %
+107,5 vs self
AL
ALKS—
Alkermes PLC
$49,53
8,2B USDP/E
39,8x
— vs self
Div yield
—
— vs self
ROE
8,4 %
+40,4 vs self
PI
PIII—
P3 Health Partners Inc
$10,20
73,8M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
95,3 %
+127,4 vs self
OR
ORGO—
Organogenesis Holdings Inc
$2,38
306,2M USDP/E
9,0x
— vs self
Div yield
—
— vs self
ROE
8,5 %
+40,6 vs self
NA
NAGE—
Niagen Bioscience Inc
$3,53
281,1M USDP/E
17,4x
— vs self
Div yield
—
— vs self
ROE
22,7 %
+54,8 vs self
SP
SPRY—
Ars Pharmaceuticals Inc
$5,51
547,1M USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-149,9 %
-117,9 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 44 %
EPS
Consensus EPS
-4,94
Predicted surprise
-0,05
Beat probability
44 %
Analysts
24
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,01 · as of 2026-08-01 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -4,94 |
| Revenue | —no estimate | —no estimate | 28,6M USD |
| Operating income | —no estimate | —no estimate | -525,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 3 %
Probability
3 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-20 · 1,0× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution24 analysts
Strong buy4
Buy9
Hold11
Sell0
Strong sell0
12-month price target$82,53 · Median $76,00
Low $44,00High $291,00
Operating income · consensus-525,9M USD
EPS surprise
−9,3 %
reported vs consensus · miss
Revenue surprise
−87,7 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$44,00
Mean$82,53
Median$76,00
High$291,00
Spot$49,92
+65.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-18 933,7 %Bottom quartile
Net Margin-16 569,8 %Bottom quartile
ROE-30,3 %Below median
Capex / Rev-738,3 %Bottom quartile
D/E0,00Above median
Cash Conv0,59Below median
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-20 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 449 934 sh12 exercises · 21 grants14 insiders
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Director · Stock Option (Right to Buy) → Common SharesAcquired 13 000 @ $51,84grant · 2026-06-05
- Chief Financial Officer · Restricted Stock Units → Common SharesAcquired 19 500grant · 2026-05-29
- General Counsel and Secretary · Restricted Stock Units → Common SharesAcquired 17 000grant · 2026-05-29
- Chief Medical Officer · Restricted Stock Units → Common SharesAcquired 22 000grant · 2026-05-29
- Chief Medical Officer · Restricted Stock Units → Common SharesDisposed 10 000exercise · 2026-05-28
- General Counsel and Secretary · Restricted Stock Units → Common SharesAcquired 25 000grant · 2026-03-20
- General Counsel and Secretary · Stock Option (Right to Buy) → Common SharesAcquired 38 499 @ $46,24grant · 2026-03-20
- General Counsel and Secretary · Restricted Stock Units → Common SharesDisposed 6 250exercise · 2026-03-20
- Chief Medical Officer · Restricted Stock Units → Common SharesAcquired 30 000grant · 2026-03-20
- Chief Medical Officer · Stock Option (Right to Buy) → Common SharesAcquired 38 499 @ $46,24grant · 2026-03-20
- Chief Financial Officer · Restricted Stock Units → Common SharesDisposed 6 250exercise · 2026-03-20
- Chief Financial Officer · Restricted Stock Units → Common SharesAcquired 27 500grant · 2026-03-20
- Chief Financial Officer · Stock Option (Right to Buy) → Common SharesAcquired 38 499 @ $46,24grant · 2026-03-20
- Director, Chief Executive Officer · Restricted Stock Units → Common SharesDisposed 19 687exercise · 2026-03-20
- Director, Chief Executive Officer · Restricted Stock Units → Common SharesAcquired 81 875grant · 2026-03-20
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common SharesAcquired 114 249 @ $46,24grant · 2026-03-20
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
Source documents
- CRSP.O Market data — financials · 2026-05-27
- CRISPR Therapeutics AG Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,10 %$0M
- Investment Managers · as of 2026-03-310,01 %$84M
- Investment Managers · as of 2026-03-310,01 %$56M
- Investment Managers · as of 2026-03-310,01 %$49M
- Investment Managers · as of 2026-03-310,01 %$113M
- Investment Managers · as of 2026-03-310,01 %$189M
- Investment Managers · as of 2026-03-310,01 %$38M
- Institutional Investor · as of 2026-03-310,00 %$93M
- Investment Managers · as of 2026-03-310,00 %$23M
- Investment Managers · as of 2024-06-300,00 %$150M
- Brokerage Firms · as of 2026-03-310,00 %$10M
- Institutional Investor · as of 2026-03-310,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$15M
- Brokerage Firms · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$20M
- Institutional Investor · as of 2022-09-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$32M
- Investment Managers · as of 2025-12-310,00 %$119M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Samarth KulkarniChairman of the Board, Chief Executive Officer
Insider activity
Net selling0 buys · 12 sellsnet -$3,3M4 insiders · last 365d
- Chief Medical Officer · Common SharesSold 3 786 @ $55,62$211K · 2026-05-29
- Chief Medical Officer · Common SharesOther 10 000 · 2026-05-28
- Director, Chief Executive Officer · Common SharesSold 10 020 @ $46,78$469K · 2026-03-23
- General Counsel and Secretary · Common SharesSold 3 182 @ $46,78$149K · 2026-03-23
- Chief Financial Officer · Common SharesSold 3 708 @ $46,78$173K · 2026-03-23
- Director, Chief Executive Officer · Common SharesOther 19 687 · 2026-03-20
- General Counsel and Secretary · Common SharesOther 6 250 · 2026-03-20
- Chief Financial Officer · Common SharesOther 6 250 · 2026-03-20
- Chief Financial Officer · Common SharesSold 4 021 @ $48,26$194K · 2026-03-16
- Chief Medical Officer · Common SharesSold 3 150 @ $48,26$152K · 2026-03-16
- Chief Financial Officer · Common SharesSold 5 848 @ $48,26$282K · 2026-03-16
- Chief Financial Officer · Common SharesOther 750 · 2026-03-16
- General Counsel and Secretary · Common SharesSold 3 450 @ $48,26$166K · 2026-03-16
- Director, Chief Executive Officer · Common SharesSold 10 349 @ $48,26$499K · 2026-03-16
- Director, Chief Executive Officer · Common SharesOther 20 625 · 2026-03-14
- Chief Financial Officer · Common SharesOther 6 875 · 2026-03-14
- Chief Financial Officer · Common SharesOther 10 000 · 2026-03-14
- Chief Medical Officer · Common SharesOther 8 125 · 2026-03-14
- General Counsel and Secretary · Common SharesOther 6 875 · 2026-03-14
- Director, Chief Executive Officer · Common SharesSold 9 798 @ $52,80$517K · 2026-03-11
- General Counsel and Secretary · Common SharesSold 2 800 @ $52,80$148K · 2026-03-11
- General Counsel and Secretary · Common SharesOther 5 500 · 2026-03-10
- Director, Chief Executive Officer · Common SharesOther 19 250 · 2026-03-10
- Director, Chief Executive Officer · Common SharesSold 6 967 @ $52,58$366K · 2026-02-19
- Director, Chief Executive Officer · Common SharesOther 13 250 · 2026-02-18
Short positioning
19.8Mshares short-2.9% vs prior
11.56days to cover
46.2%short of daily vol
467.7Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CRSP.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -8.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -90.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -0.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 10.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 1.0%Derived (calculated)
- Net margin (FY 2025-12-31): -16,569.8%Derived (calculated)
- Return on equity (FY 2025-12-31): -30.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -25.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 13.32xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.18xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -51.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 16.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -49.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -49.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -58.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -141.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -42.4%Derived (calculated)
- Current assets (annual): USD 1.99BSEC XBRL filing
- Total assets (annual): USD 2.27BSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -6SEC XBRL filing
- Current liabilities (annual): USD 149.12MSEC XBRL filing
- Pre-tax income (annual): USD -577.97MSEC XBRL filing
- R&D expense (annual): USD 284.81MSEC XBRL filing
- Operating income (annual): USD -664.57MSEC XBRL filing
Showing 24 of 57 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-08-03EVENTQ2 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-25 03:10 UTCHOLDERInstitutional holding changed
2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-21 02:57 UTCHOLDERInstitutional holding changed
2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-05 00:00 UTCINSIDER10 insider transactions — 2026-06 10 derivative
2026-06-05INSIDERGeorge Simeon acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERMahatme Sandesh acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERMorrison Briggs acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERRommel Christian acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERTreco Douglas A acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERBehbahani Ali acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERFardis Maria acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERFleming Harold Edward acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERGreene John acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-06-05INSIDERHigh Katherine A acquired 13.0k sh Stock Option (Right to Buy) — Director
2026-05-29 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $211k 4 derivative
2026-05-29INSIDERPatel Naimish sold 3.8k sh Common Shares — Chief Medical Officer ~$211k
2026-05-29INSIDERKASINGER JAMES R. acquired 17.0k sh Restricted Stock Units — General Counsel and Secretary
2026-05-29INSIDERPatel Naimish acquired 22.0k sh Restricted Stock Units — Chief Medical Officer
2026-05-29INSIDERPrasad Raju acquired 19.5k sh Restricted Stock Units — Chief Financial Officer
2026-05-28INSIDERPatel Naimish transacted 10.0k sh Common Shares — Chief Medical Officer
2026-05-28INSIDERPatel Naimish disposed of 10.0k sh Restricted Stock Units — Chief Medical Officer
2026-03-23 00:00 UTCINSIDER39 insider transactions — 2026-03 · net sell $2.8M 18 derivative
2026-03-23INSIDERKulkarni Samarth sold 10.0k sh Common Shares — Director, Chief Executive Officer ~$469k
2026-03-23INSIDERKASINGER JAMES R. sold 3.2k sh Common Shares — General Counsel and Secretary ~$149k
2026-03-23INSIDERPrasad Raju sold 3.7k sh Common Shares — Chief Financial Officer ~$173k
2026-03-20INSIDERKulkarni Samarth transacted 19.7k sh Common Shares — Director, Chief Executive Officer
2026-03-20INSIDERKASINGER JAMES R. transacted 6.2k sh Common Shares — General Counsel and Secretary
Showing the 40 most recent of 68 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage